Photo by bermixstudio from unsplash
The authors would like to acknowledge Andreas Kuglstatter and Christine Lukacs (Roche Pharma Research and Early Development), who provided an initial analysis of the binding mode of compound 3 in… Click to show full abstract
The authors would like to acknowledge Andreas Kuglstatter and Christine Lukacs (Roche Pharma Research and Early Development), who provided an initial analysis of the binding mode of compound 3 in relation to Roche compound RN486 that formed the basis of our interpretation as depicted in Figure 4 and as described in the manuscript. J. W. Cuozzo,* P. A. Centrella, D. Gikunju, S. Habeshian, C. D. Hupp, A. D. Keefe, E. A. Sigel, H. H. Soutter, H. A. Thomson, Y. Zhang, M. A. Clark
Keywords:
mode;
discovery potent;
corrigendum discovery;
potent btk;
btk inhibitor;
binding mode
Journal Title: ChemBioChem
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: ChemBioChem
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!